LQDA vs. INVA, CNTA, MGNX, SAVA, TYRA, IMNM, OCUL, ABVX, SPRY, and ARQT
Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Innoviva (INVA), Centessa Pharmaceuticals (CNTA), MacroGenics (MGNX), Cassava Sciences (SAVA), Tyra Biosciences (TYRA), Immunome (IMNM), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Liquidia (NASDAQ:LQDA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Liquidia has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Innoviva has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
64.5% of Liquidia shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 31.6% of Liquidia shares are owned by insiders. Comparatively, 1.4% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Liquidia and Liquidia both had 6 articles in the media. Innoviva's average media sentiment score of 0.82 beat Liquidia's score of 0.62 indicating that Innoviva is being referred to more favorably in the news media.
Innoviva received 112 more outperform votes than Liquidia when rated by MarketBeat users. However, 66.30% of users gave Liquidia an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Liquidia presently has a consensus target price of $21.00, indicating a potential upside of 74.13%. Given Liquidia's higher probable upside, equities analysts plainly believe Liquidia is more favorable than Innoviva.
Innoviva has a net margin of 58.21% compared to Liquidia's net margin of -448.89%. Innoviva's return on equity of 28.94% beat Liquidia's return on equity.
Summary
Innoviva beats Liquidia on 11 of the 16 factors compared between the two stocks.
Get Liquidia News Delivered to You Automatically
Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Liquidia Competitors List
Related Companies and Tools
